Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

BioVie Inc.

NASDAQ: BIVI ↗$1.65 USD~$0.1B MCAP
#Parkinson's Disease#Alzheimer's Disease#Liver Disease#Neurodegeneration

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease and long COVID, as well as advanced liver disease.

Company Info

Sector:Biotechnology
Headquarters:Newton, Massachusetts, USA
Founded:2013
Website:bioviepharma.com/

Upcoming Milestones & Key Dates

August 2026
Corporate

Live investor webinar on SUNRISE-PD topline results

Q4 2026
Clinical

Next clinical milestones for bezisterim programs

Clinical Development Pipeline

Bezisterim (NE3107)

Target: Inflammatory/insulin-resistance pathway
Early Parkinson's disease
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Bezisterim (NE3107)

Target: Inflammatory/insulin-resistance pathway
Alzheimer's disease
Preclinical
Phase 1
Phase 2
Phase 3
Approved

BIV201

Target: Vasopressin receptor agonist
Advanced liver disease / ascites
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Cuong Do

President and Chief Executive Officer

Careers & Job Openings

See all open roles

Multiple Departments
See careers page
Apply Now →